Trial intelligence / Profile preview

Phase 2b study of BMS-790052 in combination with peginterferon for chronic hepatitis C genotype 1

2010-018295-24Phase 2Completed

Sponsor
Bristol Myers Squibb
Start
May 2010
Modality
Small Molecules
Countries
1
01

Overview

Phase 2 trial of daclatasvir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoint: Rapid virologic response (RVR) at week 4. Started May 2010; status: completed.

02

Drugs

daclatasvir
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2010-018295-24.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-018295-24.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call